Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Change in Receivables (2016 - 2020)

Viridian Therapeutics, Inc.\DE has reported Change in Receivables over the past 7 years, most recently at -$48000.0 for Q4 2020.

  • Quarterly results put Change in Receivables at -$48000.0 for Q4 2020, changed N/A from a year ago — trailing twelve months through Dec 2020 was -$99000.0 (changed N/A YoY), and the annual figure for FY2020 was -$99000.0, down 217.86%.
  • Change in Receivables for Q4 2020 was -$48000.0 at Viridian Therapeutics, Inc.\DE, up from -$191000.0 in the prior quarter.
  • Over the last five years, Change in Receivables for VRDN hit a ceiling of $3.4 million in Q1 2018 and a floor of -$3.6 million in Q2 2018.
  • Median Change in Receivables over the past 5 years was $96000.0 (2017), compared with a mean of $61210.5.
  • Biggest five-year swings in Change in Receivables: crashed 2044.12% in 2016 and later surged 7363.64% in 2017.
  • Viridian Therapeutics, Inc.\DE's Change in Receivables stood at $11000.0 in 2016, then surged by 7363.64% to $821000.0 in 2017, then crashed by 265.41% to -$1.4 million in 2018, then skyrocketed by 170.32% to $955000.0 in 2019, then tumbled by 105.03% to -$48000.0 in 2020.
  • The last three reported values for Change in Receivables were -$48000.0 (Q4 2020), -$191000.0 (Q3 2020), and $244000.0 (Q2 2020) per Business Quant data.